European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading

MT Newswires Live
Oct 24

European equities traded in the US as American depositary receipts were little changed late Friday morning, edging 0.03% higher to 1,593.26 on the S&P Europe Select ADR Index, which is up about 0.5% for the week.

From continental Europe, the gainers were led by pharmaceutical company Sanofi (SNY) and biotech firm Evaxion (EVAX), which rose 3.8% and 4.8% respectively. They were followed by biopharmaceutical companies DBV Technologies (DBVT) and Genfit (GNFT), which were up 4.9% and 1.2% respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and software firm SAP (SAP), which fell 7.9% and 2% respectively. They were followed by petroleum refiner Equinor (EQNR) and medical device manufacturer EDAP TMS (EDAP), which were down 2.8% and 2% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Akari Therapeutics (AKTX), which advanced 5% and 2.8% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and hospitality company InterContinental Hotels Group (IHG), which increased 2.7% and 1.9% respectively.

The decliners from the UK and Ireland were led by pharmaceutical company GSK (GSK) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which dropped 5.1% and 9.7% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10